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A B S T R A C T
It is widely recognised that drug solubility within the gastrointestinal tract (GIT) differs from values determined
in a simple aqueous buffer and to circumvent this problem measurement in biorelevant fluids is determined.
Biorelevant fluids are complex mixtures of components (sodium taurocholate, lecithin, sodium phosphate, so-
dium chloride, pancreatin and sodium oleate) at various concentrations and pH levels to provide systems si-
mulating fasted (FaSSIF) or fed (FeSSIF) intestinal media. Design of Experiment (DoE) studies have been applied
to investigate FaSSIF and FeSSIF and indicate that a drug's equilibrium solubility varies over orders of magni-
tude, is influenced by the drug type and individual or combinations of media components, with some of these
interactions being drug specific. Although providing great detail on the drug media interactions these studies are
resource intensive requiring up to ninety individual experiments for FeSSIF. In this paper a low sample number
or reduced DoE system has been investigated by restricting components with minimal solubility impact to a
single value and only investigating variations in the concentrations of sodium taurocholate, lecithin, sodium
oleate, pH and additionally in the case of fed media, monoglyceride. This reduces the experiments required to
ten (FaSSIF) and nine (FeSSIF). Twelve poorly soluble drugs (Ibuprofen, Valsartan, Zafirlukast, Indomethacin,
Fenofibrate, Felodipine, Probucol, Tadalafil, Carvedilol, Aprepitant, Bromocriptine and Itraconazole) were in-
vestigated and the results compared to published DoE studies and literature solubility values in human intestinal
fluid (HIF), FaSSIF or FeSSIF. The solubility range determined by the reduced DoE is statistically equivalent to
the larger scale published DoE results in over eighty five percent of the cases. The reduced DoE range also covers
HIF, FaSSIF or FeSSIF literature solubility values. In addition the reduced DoE provides lowest measured so-
lubility values that agree with the published DoE values in ninety percent of the cases. However, the reduced
DoE only identified single and in some cases none of the major components influencing solubility in contrast to
the larger published DoE studies which identified multiple individual components and component interactions.
The identification of significant components within the reduced DoE was also dependent upon the drug and
system under investigation. The study demonstrates that the lower experimental number reduces statistical
power of the DoE to resolve the impact of media components on solubility. However, in a situation where only
the solubility range is required the reduced DoE can provide the desired information, which will be of benefit
during in vitro development studies. Further refinements are possible to extend the reduced DoE protocol to
improve biorelevance and application into areas such as PBPK modelling.
1. Introduction
Poorly soluble drugs (Biopharmaceutical Classification System
(BCS) Class II and IV [2] represent the majority of newly developed
molecules over the last twenty years linked to the introduction of high
throughput screening systems [17]. Due to this shift the pharmaceutical
industry is constantly striving to facilitate new formulation techniques
that can aid the development of compounds with low aqueous solubility
[31] while also developing new in-vitro methods that further inform on
the gastrointestinal solubility of these compounds [16].
Gastrointestinal tract (GIT) media contains secretions including bile
salt, products of digestion and electrolytes, which influence buffer ca-
pacity induce pH variations along the length of the tract and can induce
a number of other changes within the tract, which may influence drug
solubility [6]. These factors within the gastrointestinal environment
have been shown to enhance the solubility profile of a drug beyond that
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predicted during basic solubility studies in simple buffer or acid solu-
tions [34]. In particular, the composition of the primary bile compo-
nents, bile salt and lecithin, plays an important role in solubility
through the formation of mixed micelles [23]. The relationship between
bile salts and lecithin is further pronounced in the fed state where
concentrations are higher due to, bile release, food ingestion and the
presence of lipid digestion products.
Human Intestinal Fluid (HIF) would be the fluid of choice to study
drug solubility in the GIT and its subsequent effect upon oral bioa-
vailability; however, sufficient fluid is difficult to obtain, the mixtures
are unstable due to loss of CO2 and as such this approach is not a fea-
sible option in the routine course of drug solubility studies [15,26]. A
recent publication identified updated concentration ranges in fasted
and fed state HIF with Bile salt concentrations ranging from 0.03 to
36.18mM in fasted state and 0.74–86.14mM in fed state and phos-
pholipid ranged from 0.01 to 6.33mM in fasted state and
0.6–14.39mM in fed state which correspond with previously published
literature values [4,8].This same study identified FFA ranges from 0 to
12.67mM in fasted state and 2.1–58.7 mM in fed state while MAG
ranged from 0 to 3.30mM in fasted state and 0–34.4mM in fed state. It
should be noted that these values include extreme values and outliers.
Simulated intestinal fluids (SIF) to mimic gastrointestinal fluid have
been used extensively in the last two decades to aid in vitro drug de-
velopment and formulation studies [20,33] with varied constituents
and compositions based around current literature values. Recent work
within our group has focused on the investigation of gastrointestinal
solubility of BCS Class II compounds through the use of simulated fluids
in statistical Design of Experiment (DoE) style investigations. This al-
lows media components such as bile salt, pH, oleate, lecithin and mono-
glyceride concentrations to be systematically examined to provide an
overall view of the individual component’s role and interactions within
a compound’s solubility envelope [1,14,25,38]. Myers [22] described a
DoE system as being able to investigate the effects of numerous variable
factors to be studied in one single experiment leading to enhanced
understanding of the system in a time and consumable efficient manner.
Initially, DoE experiments were undertaken with the level of compo-
nents varied in line with literature values [4] with the first DoE study
[14] investigating the fasted state environment, whilst the second study
[38] examined the fed state. Although these studies provided novel,
interesting and valuable results a subsequent study was carried out to
combine both the fasted and fed studies with a reduced experimental
load [25] using a 1/8 fraction factorial DoE. This approach reduced the
number of samples required for the DoE however, differentiation could
no longer be observed between the fasted and fed states leading to the
design of a dual level DoE [1]. This was a customised 1/8 fraction
factorial design incorporated into the DoE approach described in the
Perrier publication, which reduced samples to 32 individual experi-
ments and allowed for results to distinguish between fasted and fed
environments. An alternative approach looked to assess the influence of
SIF composition on the solubility of BCS class II compounds utilising a
DoE with reduced media parameters [19], which also allows for a
smaller number of experiments. However, a recent solubility in-
vestigation of SIF composition applying an alternate four component
mixture design statistical technique [7] indicates that solubility varia-
bility is inversely related to the number of amphiphilic components
present. Implying that the balance between media component numbers
and experimental data point numbers will be important.
Evaluation of all previous DoE protocols alongside pharmaceutical
industry requests led to a desire to construct a more concise DoE that
further reduced the number of individual experiments required whilst
still allowing analysis of component variation within SIF. This study
describes a new statistical investigation of equilibrium solubility of oral
drugs in fasted (Table 1) and fed (Table 2) SIF using a reduced dual
level DoE. The current industrial standard for SIF in solubility studies is
either fasted simulated intestinal fluid (FaSSIF) or fed simulated in-
testinal fluid (FeSSIF) [9] and as such they have been included as centre
points for analysis within this DoE. The resultant DoE comprises of 10
experiments in the fasted state study and 9 in the fed state giving a
greatly reduced overall number of experiments, while still allowing the
study of five parameters of interest (bile salt, lecithin, fatty acid, mono-
glyceride and pH). Buffer and salt were held at constant values as
shown in Tables 1 and 2 following previous experiments [25,38] that
showed both these constituents to have no significant solubility impact.
The equilibrium solubility of 12 BCS class II drugs was studied: 3 acids
(indomethacin, ibuprofen and valsartan), 5 bases (itraconazole, tada-
lafil, carvedilol, aprepitant and bromocriptine), 3 neutral drugs (feno-
fibrate, felodipine and probucol), and finally zafirlukast, which behaves
in this system as an acid due to its pKa value of 4 [18,35].
2. Materials and methods
2.1. Materials
Sodium taurocholate (NaTC), ammonium formate, sodium chloride
(NaCl), chloroform, formic acid, monosodium phosphate (NaH2PO4),
fenofibrate, indomethacin, itraconazole, bromocriptine, sertraline,
valsartan and ibuprofen were purchased from Sigma Aldrich Poole,
Dorset UK. Lecithin S PC (phosphatidylcholine (PC) from Soybean
“98%”) was purchased from Lipoid. Glycerol mono oleate (GMO) was
obtained from CRODA Healthcare. The active pharmaceutical in-
gredients felodipine, probucol, aprepitant, tadalafil, carvedilol and za-
firlukast were provided through OrBiTo by Dr. R. Holm Head of
Preformulation, Lundbeck, Denmark. Table 3 outlines the physico-
chemical properties of the selected compounds. Sodium oleate (SO) was
obtained from BDH Chemical Ltd. Poole England. FaSSIF V1 and FeSSIF
V2 were purchased from Biorelevant.com. The analytical solvents me-
thanol and acetonitrile were of HPLC grade (VWR, UK). All water was
ultrapure Milli-Q water.
2.2. Design of experiment and data analysis
A fully customised design of experiment with 4 or 5 factors (fasted
or fed with either a component concentration or a system parameter
such as pH) and three levels (low, mid and high) was constructed using
Minitab®17.2.1. The selection of the different factors used in the design
of the experiment were based on a survey of published literature of
simulated fasted media variants [36,21,12,13,11,15,24,32,34] and our
own previous DOE results. Minitab generated 10 different experiments
for fasted and 9 different experiments for fed using various combina-
tions and levels of the 4 or 5 factors as shown in Tables 1 and 2 (no
centre point and no replicate) at either low, high or mid-levels based
upon previous literature reported values [14]. This design permits the
analysis of the impact on solubility of individual factor effects but does
not permit the analysis of 2-way or higher factor interactions due to the
design of this DOE and its limited number of experiments. The Mann-
Whitney test was used in Minitab® to evaluate differences between two
data sets.
2.3. Equilibrium solubility measurements
2.3.1. Preparation of stock solutions for fasted media experiments and
FaSSIF
Sodium oleate (SO) (73mg) was added to a 5mL flask under gentle
heat, to aid dissolution and made to final volume with water, the so-
lution was then kept at 50 °C to aid solubilisation. Bile salt (NaTC,
238mg) was added to a 5mL flask and made up to final volume with
water. Phospholipid (PC) (59mg) was dissolved with a few ml of
chloroform and dried under a stream of nitrogen then reconstituted
with water to the final volume of 5mL. Buffer (NaH2PO4, 294mg) was
added to a 5mL flask and made up to final volume with water. Salt
(NaCl, 464mg) was added to a 5mL flask and made up to final volume
with water. Stock solutions were designed to be 15 times greater than
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the highest DoE concentration levels requiring the addition of a fixed
volume in each tube as indicated in the supplementary material in
supplementary table 1.
To prepare FaSSIF V1, buffer (NaH2PO4, 40mg) was added to NaCl
(60mg) in 10mL flask with 8mL of water, pH was adjusted to 6.5 and
FaSSIF V1 powder (20mg) was added, stirred until completely dis-
solved and made up to final volume with water (see Table 4).
2.3.2. Preparation of stock solutions for Fed media experiments
NaTC, PC and GMO were weighed into a flask with a few mL of
chloroform and stirred to dissolve all the solid material. Chloroform
was evaporated off with a stream of nitrogen gas to ensure a dry film is
produced. Water (3mL) was added to the dried film and stirred to
prepare a homogeneous mixture then made to final volume. The stock
solutions have been designed to be 15 times greater than the highest
concentration levels, requiring the addition of a fixed volume in each
tube as indicated in (see Table 5) and supplementary material table 2.
2.3.3. Preparation of sodium oleate, buffer, salt and FeSSIF V2 in fed media
Buffer (NaH2PO4 4.7 g) was added to a 50mL flask and made to
final volume with water. Salt (NaCl, 550mg) was added to a 5mL flask
and made to final volume with water. Sodium oleate (1.49 g) was added
to a 10mL flask under gentle heat to aid dissolution and made to final
volume with water, the solution was then kept at 50 °C to aid solubi-
lisation. These stock solutions were designed to be 15 times greater
than the highest concentration levels, requiring the addition of a fixed
volume in each tube as indicated in supplementary material table 3.
To prepare FeSSIF V2, buffer, NaOH (0.03 g) and maleic acid
(0.06 g) was added to NaCl (0.07 g) and dissolved in about 8mL of
water. pH was adjusted to 5.8 and FeSSIF V2 powder (0.1 g) was added.
This was stirred until completely dissolved and made up to volume in
10mL flask. FeSSIF V2 was chosen instead of V1 as this contained
oleate and Glyceryl Mono Oleate and is therefore closest to our original
DOE systems allowing more direct comparison.
2.3.4. Preparation of individual solutions
An excess of drug (approximately 10mg) above its solubility limit
was added to all 15mL centrifuge tubes apart from Ibuprofen which
had 20mg added due to higher solubility. The required amount of each
stock solution and water was added to each of these tubes as shown in
supplementary material table 3, to provide a final volume of 4mL in the
15mL centrifuge tube and pH adjusted to 5, 5.8 or 7 using 0.1 M HCl or
0.1 M KOH (no more than 10% of the final volume was added during
pH adjustment). Variation in opacity and emulsion like appearance is
observed between tubes. Tubes were shaken for 1 h at room tempera-
ture, pH re-adjusted if required and then placed in an orbital shaker for
24 h at 37 °C and 240 rpm. Following incubation, the tubes were
checked for the presence of solid drug, then centrifuged (13,000 rpm,
5min) and the supernatant (500 μL) was sampled to determine the
solubilised drug concentration by HPLC. The HPLC method has been
previously validated to quantify the concentration of the drug of in-
terest (Ref: Perrier 2018). Calibration curves were constructed for each
drug and the subsequent equation of the line was used to quantify the
Table 1
Fasted state concentration levels- levels employed in reduced range design of experiment.
Parameter All Low All High Mid 1 Mid 2 FaSSIF V1 with oleate FaSSIF V1
Bile salt (mM) 1.5 5.9 1.5 5.9 3 3
Lecithin (mM) 0.2 1 0.75 0.75 0.75 0.75
Fatty acid (mM) 0.41 3.2 1.64 1.64 1.64 –
Buffer (mM) Phosphate 28.4
Salt (mM) NaCl 105.9
pH 5 and 7 6.5 6.5
Table 2
Fed media concentration levels- levels employed in reduced range design of
experiment.
Parameter All Low All High Mid 1 Mid 2 FeSSIF V2
Bile salt (mM) 3.6 24 3.6 15 10
Lecithin (mM) 0.5 4.8 2 2 2
Fatty acid (mM) 6.6 32.8 19.7 19.7 0.8
Monoglyceride (mM) 1 6.5 5 5 5
Buffer (mM) Phosphate 45 Maleic acid 19
Salt (mM) NaCl 125.5
pH 5 and 7 5.8
Table 3
Physicochemical properties.
Drug MW Log P pKa PSA (polar
surface
area)
Melting
point
Intrinsic
Solubility
(µM)
Indomethacin 357.787 3.8 4.5 68.53 158 16.6
Ibuprofen 206.29 3.51 4.9 37.3 76 245.47
Valsartan 435.519 1.5 3.9 112.07 116
Itraconazole 705.64 5.66 100.79 166.2
Tadalafil 389.404 1.64 15.17 74.87 301 19.83
Carvedilol 406.474 3.91 7.8 75.74 114.5 24.6
Aprepitant 534.427 4.8 9.7 75.19 254 1.5
Bromocriptine 750.7 3.2 6.68 118.21 192 3.67
Fenofibrate 360.831 5.24 52.6 80.5 0.81
Felodipine 384.259 3.86 64.63 145 0.276
Probucol 516.844 10 40.46 126 0.0116
Zafirlukast 575.676 6.4 4 115.73 139
Table 4
Fasted media composition (mM) – Stock mixture concentrations.
Media number levels Bile salt Lecithin Oleate pH
1 All high 5.9 1 3.2 5
2 mid 2 5.9 0.75 1.64
3 mid 1 1.5 0.75 1.64
4 All low 1.5 0.2 0.41
5 fassif v1 3 0.75 0 6.5
6 All high 5.9 1 3.2 7
7 mid 2 5.9 0.75 1.64
8 mid 1 1.5 0.75 1.64
9 All low 1.5 0.2 0.41
10 fassif v1+ oleate 3 0.75 1.64 6.5
Table 5
Fed media composition (mM)- Stock mixture concentrations.
Media levels Bile salt Lecithin Oleate Monoglyceride pH
1 All high 24 4.8 32.8 6.5 5
2 mid 2 15 2 19.7 5 5
3 mid 1 3.6 2 19.7 5 5
4 All low 3.6 0.5 6.6 1 5
5 FeSSIF V2 10 2 0.8 5 5.8
6 All high 24 4.8 32.8 6.5 7
7 mid 2 15 2 19.7 5 7
8 mid 1 3.6 2 19.7 5 7
9 All low 3.6 0.5 6.6 1 7
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drug concentration. Assays conditions are presented in Table 6.
For each drug it is possible to statistically compare the current DoE
results in either the fasted or fed state with the corresponding published
data providing a possible total of twenty four comparisons. However in
four cases, ibuprofen, valsartan, bromocriptine, itraconazole in the
fasted state comparable large scale DoE results were not available, re-
ducing the number of possible comparisons to twenty. Due to the small
number of data points within the reduced DoE and previous reports that
DoE solubility distributions are not universally normally distributed [1]
a non-parametric Mann Whitney comparison was performed. Where a
statistically significant difference was observed this has been noted on
the relevant figure along with the determined level of significance.
3. Results and discussion
3.1. Solubility range
The individual equilibrium solubility measurements from the re-
duced DoE under fasted and fed conditions for the twelve drugs tested
are presented in Figs. 1–12. Where available previously published data
from the larger fasted [14] and fed [38] DoE studies are plotted
alongside as box and whisker plots, along with individual solubility
measurements in the relevant simulated or sampled intestinal fluids
[3].
A significant difference was detected in three out of the twenty
available comparisons, ibuprofen and probucol in the fed state and
tadalafil in the fasted state. In all other comparisons no statistically
significant difference was detected indicating agreement between the
DoE studies and determination of solubility ranges in eighty five
percent of the cases.
For each drug there are also four potential comparisons against
reported literature solubility values resulting from either a fasted or fed
condition determined in either SIF or HIF media. This provides a total
of forty eight possible comparisons however, only twenty three ap-
propriate literature solubility measurements were available and in
twenty of these the reported solubility value lies within the range of the
reduced DoE in the respective fasted or fed conditions. Only in-
domethacin, itraconazole and probucol have reported solubility values
outside of the reduced DoE solubility range. This comparison indicates
that in approximately eighty five percent of cases the reduced DoE is
determining solubility values that are comparable to reported in-
dividual literature solubility data in either fasted or fed HIF or SIF.
3.2. Lowest solubility values
A key parameter of the original BCS system [2] and modifications
[5,29] is the dose/solubility ratio [28], with a lower value optimal for
drug absorption. This implies that the lowest measured solubility is the
critical value since this represents a worst case scenario for oral drug
administration. A comparison of the measured lowest solubility values
is presented in Table 7 as a ratio of either fasted or fed full DoE lowest
value divided by the comparable reduced DoE lowest value. The mea-
sured solubility values will be intrinsically influenced by variation in
the media component concentrations, ratios and ranges [7] applied
within the three DoE systems and they cannot be considered equivalent
(see introduction). In addition, differing DoE designs (fasted: fractional
factorial and fed: D-optimal) which are also not statistically equivalent
have been applied. To allow for these experimental, statistical and
Table 6
HPLC Assay Conditions. Apparatus: Agilent Technologies 1260 Series Liquid Chromatography. Software: Clarity Chromatography data system, Column: ACE 3 C18
50×3.0mm id 3 µm.
ACN: Acetonitrile, MeOH: Methanol, MP: Mobile Phase.
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concentration differences a ratio within a 10 fold variation (ie a ratio of
between 10 and 0.1) has been arbitrarily applied as equivalence. Out of
the twenty possible comparisons two or 10% are outside the 10 fold
ratio and in all these cases the reduced DoE has a higher solubility
value. The two cases are evenly split with one in the fasted state
(probucol) and one in the fed state (bromocriptine). For the acidic
compounds with the exception of zafirlukast in the fasted systems the
ratio is very close to 1, indicating a close agreement between the full
and reduced systems, probably related to the comparable pH values
employed since pH is the main solubility driver for acidic compounds,
(m
M
)
Fig. 1. Design of experiment equilibrium solubility measurement of
Indomethacin. Legend: Equilibrium solubility measurements for Indomethacin
in DOE media compositions detailed in Table 1. Solubility values found in re-
duced fasted DOE shown as , reported solubility values found in original
fasted DOE shown as , reported solubility values found in fasted simulated
intestinal fluid shown as , reported solubility values found in fasted human
intestinal fluid shown as [3], solubility values found in reduced fed DOE
shown as , solubility values found in original Fed DOE shown as [14],
reported solubility values found in fed simulated intestinal fluid shown as ,
reported solubility values found in fed human intestinal fluid shown as .
(m
M
)
Fig. 2. Design of experiment equilibrium solubility measurement of Ibuprofen.
Legend: Equilibrium solubility measurements for Ibuprofen in DOE media
compositions detailed in Table 1. Solubility values found in reduced fasted DOE
shown as , reported solubility values found in fasted human intestinal fluid
shown as [3], solubility values found in reduced fed DOE shown as , so-
lubility values found in original Fed DOE shown as [14]. Where relevant,
significant difference is shown in comparison bars calculated from Mann-
Whitney test, * p≤ 0.05.
(m
M
)
Fig. 3. Design of experiment equilibrium solubility measurement of Valsartan.
Legend: Equilibrium solubility measurements for Valsartan in DOE media
compositions detailed in Table 1. Solubility values found in reduced fasted DOE
shown as , solubility values found in reduced fed DOE shown as , solubility
values found in original Fed DOE shown as [14].
(m
M
)
Fig. 4. Design of experiment equilibrium solubility measurement of Zafirlukast.
Legend: Equilibrium solubility measurements for Zafirlukast in DOE media
compositions detailed in Table 1. Solubility values found in reduced fasted DOE
shown as , reported solubility values found in original fasted DOE shown as
, solubility values found in reduced fed DOE shown as , solubility values
found in original Fed DOE shown as [14].
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especially in fasted media [7], see solubility factor section. For basic
and neutral compounds the spread of solubility ratios is greater, prob-
ably related to the greater impact of media components, concentrations
and ratios [1,7,14,37,38] on the solubility of these compound cate-
gories in simulated media, see solubility factor section.
3.3. Solubility factor analysis
The DoE statistical analysis calculates if there is a relationship be-
tween individual media factors, either a component or condition (ie pH)
and solubility and can determine if a positive or negative solubility
effect is present. Only the significant factors for the reduced DoE are
(m
M
)
Fig. 5. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Itraconazole in DOE media composi-
tions detailed in Table 1. Solubility values found in reduced fasted DOE shown
as reported solubility values found in fasted simulated intestinal fluid shown
as reported solubility values for fasted human intestinal fluid shown as [3],
solubility values found in reduced fed DOE shown as solubility values found
in original Fed DOE shown as [14], reported solubility values found in fed
intestinal simulated fluid shown as and reported solubility values found in
fed human intestinal fluid shown as .
(m
M
)
Fig. 6. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Tadalafil in DOE media compositions
detailed in Table 1. Solubility values found in reduced fasted DOE shown as
reported solubility values found in original fasted DOE shown as , solubility
values found in reduced fed DOE shown as and solubility values found in
original Fed DOE shown as Where relevant, significant difference is shown
in comparison bars calculated from Mann-Whitney test, **** p≤ 0.0001.
(m
M
)
Fig. 7. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Carvedilol in DOE media compositions
detailed in Table 1. Solubility values found in reduced fasted DOE shown as
reported solubility values found in original fasted DOE shown as reported
solubility values found in fasted simulated intestinal fluid shown as reported
solubility values found in fasted human intestinal fluid shown as [3], solu-
bility values found in reduced fed DOE shown as and solubility values found
in original Fed DOE shown as [14].
(m
M
)
Fig. 8. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Aprepitant in DOE media composi-
tions detailed in Table 1. Solubility values found in reduced fasted DOE shown
as reported solubility values found in original fasted DOE shown as re-
ported solubility values found in fasted simulated intestinal fluid shown as
reported solubility values found in fasted human intestinal fluid shown as
[3], solubility values found in reduced fed DOE shown as and solubility
values found in original Fed DOE shown as [14].
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presented in Table 8 with the significant factors from the published
fasted [14] and fed [38] DoE experiments for comparison. Non-sig-
nificant factors are not included.
To determine whether the association between factor and solubility
is statistically significant, the p-value is compared to the significance
level. Standardized effect value is calculated through the Minitab sta-
tistical program and further information regarding this can be found
within Mintab Support (https://support.minitab.com/en-us/minitab/
18/help-and-how-to/modelling-statistics/doe/how-to/factorial/
analyze-factorial-design/interpret-the-results/key-results/).
Overall including both fasted or fed, in the comparable cases the
(m
M
)
Fig. 9. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Bromocriptine in DOE media compo-
sitions detailed in Table 1. Solubility values found in reduced fasted DOE shown
as solubility values found in reduced fed DOE shown as and solubility
values found in original Fed DOE shown as [14].
(m
M
)
Fig. 10. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Fenofibrate in DOE media composi-
tions detailed in Table 1. Solubility values found in reduced fasted DOE shown
as , reported solubility values found in original fasted DOE shown as , re-
ported solubility values found in fasted simulated intestinal fluid shown as ,
reported solubility values in fasted human intestinal fluid shown as [3],
solubility values found in reduced fed DOE shown as solubility values found
in original Fed DOE shown as [14] reported solubility values found in fed
intestinal simulated fluid shown as and reported solubility values found in
fed human intestinal fluid shown as .
(m
M
)
Fig. 11. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurements for Felodipine in DOE media compositions
detailed in Table 1. Solubility values found in reduced fasted DOE shown as ,
reported solubility values found in original fasted DOE shown as , reported
solubility values found in fasted simulated intestinal fluid shown as , reported
solubility values found in fasted human intestinal fluid shown as [3], solu-
bility values found in reduced fed DOE shown as , solubility values found in
original Fed DOE shown as [14] and reported solubility values found in fed
human intestinal fluid shown as .
(m
M
)
Fig. 12. Design of experiment equilibrium solubility measurements. Legend:
Equilibrium solubility measurement of Probucol in DOE media compositions
detailed in Table 1. Solubility values found in reduced fasted DOE shown as ,
reported solubility values found in original fasted DOE shown as , reported
solubility values found in fasted simulated intestinal fluid shown as , reported
solubility values found in fasted human intestinal fluid shown as [3], solu-
bility values found in reduced fed DOE shown as , solubility values found in
original Fed DOE shown as [14] and reported solubility values found in fed
human intestinal fluid shown as . Where relevant, significant difference is
shown in comparison bars calculated from Mann-Whitney test, * p≤ 0.05.
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reduced DoE detected fourteen significant factors compared to sixty
four for the published DoE studies. This can be further broken down to a
fasted comparison (eight possible comparisons) where the reduced DoE
found no significant factors for four drugs (Itraconazole, ibuprofen,
aprepitant and bromocriptine) and eleven factors overall against the
larger DoE with all drugs displaying at least one significant factor and a
total of twenty eight for the eight drugs where data is available. In the
fed state the reduced DoE found no significant factors for nine out of the
twelve drugs and only three factors overall against the larger DoE with
one drug displaying no significant factors and a total of thirty six for the
remaining eleven drugs.
For acidic drugs the most significant individual factor identified in
the original fasted [14] and fed [38] DoE was pH with a pH dependent
solubility split easily visible in the data plots especially in the fasted
state (Figs. 1–4). This can be seen as two clear groupings of points in the
reduced DoE for indomethacin (pKa= 4.5), ibuprofen (pKa=4.9) and
zafirlukast (pKa=4) but is not clear for valsartan (pKa=3.9). pKa
values were obtained from PubChem and drugbank unless specified
above. This effect can be related to the drug’s pKa, the pH of the DoE
systems (Tables 1 and 2, either pH 5 or 7) and the impact of ionisation
on solubility. This is evident in Table 8 where pH is the most common
significant factor in the reduced DoE detected in three out of four of the
fasted systems but only one out of four for the fed. The reduced de-
tection in the fed system may be due to the fact that increased am-
phiphile concentrations increase the overall solubility of acidic drugs
overwhelming pH induced ionisation [7].
For basic and neutral drugs a range of factors, pH and amphiphiles
(bile salt, phospholipid, oleate and in fed state monoglyceride) had
equivalent impact on solubility in the published fasted [14] and fed
[38] DoE systems. For the basic drugs the reduced DoE did not detect a
significant factor for three of the drugs in the fasted system and for all
drugs in the fed system. Only tadalafil (pH) and carvedilol (bile salt and
pH) in the fasted system provided significant factors with in both cases
those factors detected in the published studies. For the three neutral
drugs the pattern is slightly different with the reduced DoE detecting
one significant factor in five out of the possible six cases (fasted and fed)
with only probucol in the fed state not detecting a significant factor. In
addition for the five cases the factor detected by the reduced DoE was
either the primary or secondary factor detected by the published fasted
[14] and fed [38] DoE systems. The results indicate that for the neutral
compounds a major significant factor is detected by the reduced DoE
but that other factors with a reduced significance are not detected. For
the basic compounds the reduced DoE fails to detect significant factors,
especially in the fed state, which may indicate a specific issue related to
the basic compounds and their solubilisation by the media or that in
cases were all factors exert an equivalent solubilisation potential the
reduced number of experimental points limits discrimination. In the
case of weak bases, factors other than pH have a greater effect on their
solubilisation such as pKa and their physicochemical properties.
The reduced DoE was also not powered to detect two way interac-
tions between media factors (see methods section) and these are known
to exist from the previous DoE studies [14,38] along with three way
interactions [7].
The striking comparison is that the reduced DoE is not identifying
an equivalent number of significant solubilisation factors to the pre-
viously published results, with only the most significant factors evident
for either acidic or neutral drugs. For basic drugs the reduced DoE fails
to detect any significant factors within the media when compared to the
Table 7
Comparison of Low Solubility Point Ratios.
Fasted State Fed State
Solubility (mM) Solubility (mM)
Drug Full DoE 9 DoE Ratio * Full DoE 9 DoE Ratio *
Acidic
Indomethacin 0.048 0.050 0.96 0.060 0.046 1.3
Ibuprofen DNA 4.0 – 1.0 1.3 0.81
Valsartan DNA 1.3 – 2.5 3.1 0.81
Zafirlukast 0.00024 0.00046 0.52 0.0022 0.0031 0.70
Basic
Itraconazole DNA – 8.2× 10−5 0.00079 0.10
Tadalafil 0.010 0.0050 2.0 0.051 0.012 4.4
Carvedilol 0.10 0.013 7.7 0.059 0.27 0.22
Aprepitant 0.0023 0.010 0.23 0.04746 0.058 0.8183
Bromocriptine DNA – 0.0013 0.030 0.042
Neutral
Fenofibrate 0.0020 0.0029 0.68 0.077 0.014 5.31
Felodipine 0.0023 0.021 0.11 0.0042 0.040 0.10
Probucol 0.00016 0.0086 0.019 0.014 0.020 0.73
*Ratio= Full DoE Solubility/9 DoE Solubility.
* Ratio range set at 10 fold difference (10–0.1) values outside range in bold and
underlined.
DNA: Data Not Available.
Table 8
Factors of significance on compound solubility in the DOE experiment.
Fasted Fed
Drug Reduced Full Reduced Full
Acidic
Indomethacin pH pH, bile salt, buffer, oleate pH pH, oleate, bile salt
Ibuprofen NF DNA NF pH
Valsartan pH DNA NF pH, bile salt
Zafirlukast pH, oleate, bile salt, lecithin pH, bile salt, oleate NF pH, bile salt, oleate
Basic
Itraconazole NF DNA NF pH, oleate, bile salt, lecithin
Tadalafil pH bile salt, pH, buffer, lecithin, oleate NF bile salt, oleate
Carvedilol bile salt, pH bile salt, oleate NF bile salt, pH, buffer, oleate
Aprepitant NF oleate, pH, lecithin NF oleate, bile salt, pH
Bromocriptine NF DNA NF NF
Neutral
Fenofibrate oleate oleate, bile salt, pH, lecithin, buffer oleate oleate, bile salt, lecithin, buffer, monoglyceride
Felodipine oleate pH, oleate, lecithin, bile salt bile salt oleate, bile salt, pH, lecithin
Probucol pH pH, oleate NF bile salt, monoglyceride, oleate, lecithin, pH
NF: No statistically significant Factors detected.
DNA: Data Not Available.
Fasted significant factors [14], fed significant factors [38].
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previously published studies. This lower detection or increased re-
quirement for significance is most likely related to the lower number of
experiments performed within the DoE reducing the statistical power of
the method.
In over eighty percent of the cases examined within this reduced
DoE study the measured equilibrium solubility range in either fasted or
fed media is statistically equivalent to the solubility space previously
measured in larger published DoE studies performed within our group
[14,38]. In addition the measured lowest solubility value, which re-
present the highest risk during oral administration also agrees with the
previously published DoE values. Although this latter comparison is
based on an arbitrary solubility variation of a factor of 10 to allow for
experimental, compositional and statistical differences between the
studies. Finally, the measured solubility values also correlate well with
published literature solubility values [3] determined in either fasted or
fed, sampled or simulated intestinal fluids. Therefore, the reduced DoE
effectively measures the equilibrium gastrointestinal solubility space
for the drugs tested and presumably for other similar drugs. In the
fasted state, in most cases, the lowest solubility values are driven by the
factors affecting solubility for each drug of interest as shown in Table 8,
for example in Tadalafil; pH, bile salt, lecithin and oleate are detected
as factors affecting solubility in the full DOE which corresponds with
the lowest solubility values found in both the reduced and full DOE in
recipes containing the lowest levels of these factors. The same trend
applies in the Fed state, whether reduced or full, for example Tadalafil
solubility is driven by the factors influencing solubility, when these
factors are present at low levels in the DOE recipes the solubility is
comparatively low and when these factors are present in higher levels
we see an increase in solubility as expected.
The ability of the reduced DoE to determine which of the media
factors influence solubility is lower when compared to the previously
published DoE studies performed within our group [14,25,38]. This
lower detection or resolution is linked to the smaller number of ex-
periments performed within the reduced DoE which limits the statis-
tical power or resolution of the method. However, differences between
the performance of acidic, neutral and basic drugs indicates that cate-
gory and possibly drug specific variations in solubility are also probably
impacting the determination of significant media factors [7,38]. This
statistical limitation of the reduced DoE is also evident in the inherent
lack of detection of two way interactions between media factors, which
the previous published larger studies detected [14,25,38]. During
pharmaceutical development this latter limitation may not be critical
since assignment of a drug to a BCS classification only requires a so-
lubility determination (with respect to dose) [2,29] not identification of
the factors controlling solubility. However, it will always remain pru-
dent to check that unique solubility controlling interactions, arising
from either a single factor, combination of factors or the invariant
media components (eg phosphate) are not present.
4. Conclusions
The reduced DoE effectively determines the gastrointestinal equili-
brium solubility envelope for the drugs using a minimal matrix of so-
lubility determinations. It also provides information on the most sig-
nificant media factors contributing to solubility but this outcome is
constrained by the statistical limitations of the small experimental
numbers within the reduced DoE and possibly also influenced by the
physicochemical properties and behaviours of the drugs.
Further refinement of the reduced DoE concept is possible through a
range of modifications based on this study, previous studies and addi-
tional literature results. The media mixtures in this research are based
around previous simulated recipes [9] and do not contain cholesterol or
lysolecithin [8,27,32], components that are recognised to be present in
sampled intestinal media. Additional media components may have
added benefit in reducing the solubility variability induced by low
numbers of amphiphiles in the media mixture [7]. However, the
inclusion of additional factors will further erode, if experimental
numbers remain constant, the ability to determine factor significance. If
only solubility measurement is required this may not be critical. The
media factor concentration limits applied within the reduced DoE were
based on previously published DoE systems [14,25,38], which were
based on limited data with respect to the analysis of HIF samples [4].
The factor concentration values could be refined based on recent
structured analysis of HIF samples [27] to provide a more realistic
boundary conditions. Finally, if in vitro data is to be combined with
PKPB gastrointestinal pharmacokinetic models [10], which can in-
corporate up to seven small intestinal compartments [30], the reduced
DoE represents a manageable experimental load to determine solubility
boundaries in these compartments, assuming media component con-
centrations and conditions can be determined.
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